Leveraging Policy for Renewable Energy Development in Industrialized Countries and Emerging Markets

Renewable energy has the ability to play a dominate role in addressing both rising energy demand and the need for sustainable growth. Various policy measures and incentives have aided its growth in both developed and developing countries. This dissertation analyzes existing policies and financial mechanisms used to encourage renewable energy development through three academic papers. I first propose the carbon revenue bond as a new financing tool to complement the environmental credit markets that exist in developed countries. Stochastic modeling techniques are used to simulate future credit prices and determine bond value. Use of the carbon revenue bond is illustrated through three examples of wind energy projects in the European, Australian and New Jersey markets. In the absence of mature markets in developing countries, I develop the strategic structure matrix as a new framework to explain the various effects of policy measures in order to better shape future policy design. By synthesizing previous literature on how organizations are able to affect the diffusion of a new technology, the strategic structure matrix is able to deepen understanding of how policy can influence renewable energy growth. The explanatory power of the framework is demonstrated through a case study on the different paces of wind power diffusion in five Indian states. Lastly, I evaluate the Clean Development Mechanism as a tool to encourage investment from developed nations for renewable infrastructure in developing countries. I create an agent-based model to simulate investment decisions under different improvements to the program, providing quantitative support for the effectiveness of some improvements over others. In addition to each paper's individual contributions, the findings collectively provide important implications for the future of renewable energy policy and its ability to support continued sustainable growth

Region-specific and activity-dependent regulation of SVZ neurogenesis and recovery after stroke.

Stroke is the leading cause of adult disability. Neurogenesis after stroke is associated with repair; however, the mechanisms regulating poststroke neurogenesis and its functional effect remain unclear. Here, we investigate multiple mechanistic routes of induced neurogenesis in the poststroke brain, using both a forelimb overuse manipulation that models a clinical neurorehabilitation paradigm, as well as local manipulation of cellular activity in the peri-infarct cortex. Increased activity in the forelimb peri-infarct cortex via either modulation drives increased subventricular zone (SVZ) progenitor proliferation, migration, and neuronal maturation in peri-infarct cortex. This effect is sensitive to competition from neighboring brain regions. By using orthogonal tract tracing and rabies virus approaches in transgenic SVZ-lineage-tracing mice, SVZ-derived neurons synaptically integrate into the peri-infarct cortex; these effects are enhanced with forelimb overuse. Synaptic transmission from these newborn SVZ-derived neurons is critical for spontaneous recovery after stroke, as tetanus neurotoxin silencing specifically of the SVZ-derived neurons disrupts the formation of these synaptic connections and hinders functional recovery after stroke. SVZ-derived neurogenesis after stroke is activity-dependent, region-specific, and sensitive to modulation, and the synaptic connections formed by these newborn cells are functionally critical for poststroke recovery

Evaluating the evidence base in pharmacovigilance decision making

Introduction It has been said that through monitoring of drug safety, pharmacovigilance (PV) systems have been instrumental in assisting regulatory decisions on product safety. However, there has been no, systematic, in-depth study of this role. This thesis reports such a study conducted in the UK. On the basis of the results, suggestions are made on how PV data might be produced and used more effectively. Methods In Phase 1, a scoping study was conducted to document all changes made to UK product labelling on safety grounds over a 10 year period (September 1st 1995 to August 31st 2005). In Phase 2, all product withdrawals and major labelling changes made during the 10 year study above, were investigated in depth to determine the therapeutic group, source of ADR data cited as the reason for the change; and product survival probability, using Kaplan-Meier modelling. Phase 3, informed by Phases 1 and 2, used a web-based survey (150 respondents) and structured interviews (13 subjects) with healthcare professionals and scientists with a PV role in the NHS, pharmaceutical companies and the UK regulator, to gain views on the current procedures for handling safety issues in the UK and how these might be improved. Inferences were drawn using interpretative henomenological analysis with NVivo 8 software. Key findings Phases 1 and 2 revealed the fragmentary nature of information in the public domain and the difficulties of obtaining unpublished information. Based on public information, Phase 1 showed that 2,630 safety notices were issued affecting 688 individual products. The two main safety notice categories were drug interactions (841;32%) and side effects (537;20%). The rank order of the four most common therapeutic areas in which safety notices occurred was: CNS (23.5%)> anti-infectives (21.6%) > cardiovascular (15.2%) > cancer chemotherapy (10.8%). The ratio of Type A : Type B side effects (ADRs) was 1:3.3. Phase 2 found that of 518 eligible products launched during the study period, 9 (1.7%) were licensed and withdrawn for safety reasons. The ten-year Kaplan-Meier probability of adverse drug reactions causing the withdrawal of a new product, postmarketingwas 2.2%. All decisions were based on more than one safety data type and all involved UK yellow cards. One decision considered prescription event monitoring (PEM) data. A total of 164 important safety notices affecting 818 individual products were identified. Of 518 products launched during the study period, 56 experienced at least one major labelling change for safety reasons. The ten-year Kaplan-Meier risk of a product experiencing at least one major labelling change on safety grounds was 13.8%. As with product withdrawals, safety decisions were based on a wide range of data sources of variable quality and quantity. Variation in dissemination of the new safety information was observed. Only one fifth of safety notices warranting a ‘Dear Healthcare Professional’ letter or a monograph in ‘Current Problems in Pharmacovigilance’, were accompanied by a boxed warning in the BNF, representing an important inconsistency in notifying prescribers. As with interview participants, respondents to the on-line questionnaire had difficulties placing the yellow card reports in a formal hierarchy of evidence whilst acknowledging that the data were valuable in the decision making process. Suggested ways of improving the quality of such reports included making the reporting more accessible and training all those eligible to report. PEM studies were cited by the majority of respondents as a means of generating credible safety data and raising the general quality of the drug safety database. In terms of dissemination and education about ADRs, Drug Safety Updates (which replaced the ‘Current Problems’ publication from the MHRA in August 2007) were highly thought of; they appeared to be more popular than ‘Dear Healthcare Professional’ letters and because they were web-based, ought to be accessible by a wider audience. Conclusions Safeguarding public health is of utmost importance when making a decision whether or not to withdraw a product or amend its labelling upon the emergence of new safety data. Labelling changes should be made only on the best evidence available at the time and appropriate risk management strategies should be instigated where feasible; not only when a safety signal arises post-marketing, but when a drug is first granted a marketing authorisation. There is no general consensus on what constitutes ‘best evidence’ and rating evidence using traditional hierarchies is problematic, The GRADE hierarchy may be an exception. Improving ADR reporting should lead to improved data bases from which to draw safety conclusions. Methods of improving reporting include early instigation and enforcement of risk management plans by the regulator, education of all those eligible to report, greater transparency of regulatory decisions and better and more rapid dissemination of safety change information.EThOS - Electronic Theses Online ServiceGBUnited Kingdo

Characterizing complication risk from multisite, intermittent transfusions for the treatment of sickle cell disease

Blood transfusions are indicated for some acute complications of sickle cell disease (SCD). To characterize the SCD population at increased risk of transfusion-associated complications, Geor-gia hospital discharge data were used to estimate the frequency of intermittent transfusions and the proportion of patients receiving them at multiple institutions. Ten years of data (2007-2016) showed almost 19% of patients with SCD (1585/8529) received transfusions at more than one hospital. The likelihood of multisite transfusions increased from ages 18 through 40 and with the number of transfusions received. The results support the need to track and share transfusion his-tories in order to reduce complication risks

Animal Models of Diabetic Retinopathy (Part 2)

Diabetic retinopathy (DR) is one of the leading causes of preventable vision impairment and blindness in the working-age population worldwide. Numerous animal models have been developed for therapeutic drug screening and to further increase our understanding of the molecular and cellular pathological processes involved in DR. Following our discussion of mouse models in “Animal Models of Diabetic Retinopathy Part 1,” we describe the cellular, molecular, and morphological features of both rodent and nonrodent models of DR and their respective advantages and limitations in this chapter. To date, no animal model can holistically reproduce the pathological progression of human DR; most only display early or advanced lesions of DR. However, a thorough understanding of genotypic and phenotypic expressions of existing models will facilitate researchers’ selection of the appropriate model to simulate their desired clinical scenarios

COLECTOMY OUTCOMES IN PATIENTS OVER 65 WITH ULCERATION COLITIS

Introduction: There are limited data regarding surgical outcomes for elderly patients with Ulcerative Colitis, and we sought to examine the post operative outcomes in this population. Methods: The ACS NSQIP was queried for all patients with a diagnosis of ulcerative colitis and compared elderly patients (those aged 65 and older) to younger patients under age 65. Univariate and multivariate logistic regression was done to evaluate differences in morbidity and mortality rates. Results: 2,699 patients were analyzed, of which 493 (18.3%) were defined as elderly. Elderly patients had more comorbidities compared to younger patients but were less likely to be on preoperative steroids (47.1% vs 74.2%, p\u3c0.0001). Elderly patients had a higher proportion of emergent cases (27.6% vs 8.2%, p\u3c0.0001) and an average 3 day longer hospital stay, (p\u3c0.0001). There were no significant differences in the rates of anastomotic leak, surgical site infections or 30-day readmission. Elderly patients had a higher rate of morbidity (47.3% vs 26.8%, p\u3c0.0001) and mortality (8.9% vs 1.2%, p\u3c0.0001). Multivariate analysis showed elderly patients had significantly increased odds for morbidity (OR 2.45, 95% CI: 2.00-2.99, p\u3c0.0001) and 30-day mortality (OR 7.91, 95% CI: 4.85-12.91, p\u3c0.001). Preoperative sepsis significantly increased the risk of morbidity (OR 3.457, 95% CI: 2.27-5.26, p \u3c0.0001) and mortality (OR 3.11, 95% CI: 1.48-6.57, p\u3c0.003). Conclusions: Elderly patients with Ulcerative Colitis that undergo a colectomy are at increased risk for both morbidity and mortality. Optimizing these patients may reduce the risk, but further prospective trials are warranted to further elucidate the ideal optimization strategies.https://scholarlycommons.henryford.com/sarcd2021/1009/thumbnail.jp

Linking archival data to location A case study at the UK National Archives

Purpose The National Archives (TNA) is the UK Government's official archive. It stores and maintains records spanning over a 1,000 years in both physical and digital form. Much of the information held by TNA includes references to place and frequently user queries to TNA's online catalogue involve searches for location. The purpose of this paper is to illustrate how TNA have extracted the geographic references in their historic data to improve access to the archives. Design/methodology/approach To be able to quickly enhance the existing archival data with geographic information, existing technologies from Natural Language Processing (NLP) and Geographical Information Retrieval (GIR) have been utilised and adapted to historical archives. Findings Enhancing the archival records with geographic information has enabled TNA to quickly develop a number of case studies highlighting how geographic information can improve access to large‐scale archival collections. The use of existing methods from the GIR domain and technologies, such as OpenLayers, enabled one to quickly implement this process in a way that is easily transferable to other institutions. Practical implications The methods and technologies described in this paper can be adapted, by other archives, to similarly enhance access to their historic data. Also the data‐sharing methods described can be used to enable the integration of knowledge held at different archival institutions. Originality/value Place is one of the core dimensions for TNA's archival data. Many of the records which are held make reference to place data (wills, legislation, court cases), and approximately one fifth of users' searches involve place names. However, there are still a number of open questions regarding the adaptation of existing GIR methods to the history domain. This paper presents an overview over available GIR methods and the challenges in applying them to historical data

Summary of research projects supported by the Health Services Research Fund (HSRF) and the Health Care and Promotion Fund (HCPF)

published_or_final_versio

Phage display selected magnetite interacting Adhirons for shape controlled nanoparticle synthesis

Adhirons are robust, well expressing, peptide display scaffold proteins, developed as an effective alternative to traditional antibody binding proteins for highly specific molecular recognition applications. This paper reports for the first time the use of these versatile proteins for material binding, and as tools for controlling material synthesis on the nanoscale. A phage library of Adhirons, each displaying two variable binding loops, was screened to identify specific proteins able to interact with [100] faces of cubic magnetite nanoparticles. The selected variable regions display a strong preference for basic residues such as lysine. Molecular dynamics simulations of amino acid adsorption onto a [100] magnetite surface provides a rationale for these interactions, with the lowest adsorption energy observed with lysine. These proteins direct the shape of the forming nanoparticles towards a cubic morphology in room temperature magnetite precipitation reactions, in stark contrast to the high temperature, harsh reaction conditions currently used to produce cubic nanoparticles. These effects demonstrate the utility of the selected Adhirons as novel magnetite mineralization control agents using ambient aqueous conditions. The approach we outline with artificial protein scaffolds has the potential to develop into a toolkit of novel additives for wider nanomaterial fabrication